-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VwtfEFdHQKBtkk3RuCI6tP5w2uB6y/0QYRIhrF5XG1vFYqlvVV1hSKm1GgC4SMc2
 po8S43u3/stdNNeSK2jUBw==

<SEC-DOCUMENT>0001144204-06-026574.txt : 20060628
<SEC-HEADER>0001144204-06-026574.hdr.sgml : 20060628
<ACCEPTANCE-DATETIME>20060628171202
ACCESSION NUMBER:		0001144204-06-026574
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20060623
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060628
DATE AS OF CHANGE:		20060628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TARGETED GENETICS CORP /WA/
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23930
		FILM NUMBER:		06930777

	BUSINESS ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		2066237612

	MAIL ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v046481_8k.htm
<TEXT>
<html>
  <head>
    <title>
</title></head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>WASHINGTON,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>___________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CURRENT
      REPORT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      To Section 13 or 15(d) of the Securities Exchange Act of
      1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
                of Report (Date of earliest event reported) </font></div>
            </td>
            <td valign="top" width="40%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>June
                23, 2006</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="80%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Targeted
                Genetics Corporation</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="80%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
                name of registrant as specified in its
                charter)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="25%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington</strong></font></div>
            </td>
            <td valign="top" width="25%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>0-23930</strong></font></div>
            </td>
            <td valign="top" width="25%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>91-1549568</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or other jurisdiction </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
                incorporation)</font></div>
            </td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission
                File </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number)</font></div>
            </td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(IRS
                Employer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Identification
                No.)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="50%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1100
                Olive Way, Suite 100, Seattle, Washington</strong></font></div>
            </td>
            <td valign="top" width="25%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>98101</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
                of principal executive offices)</font></div>
            </td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Zip
                Code)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="43%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant's
                telephone number, including area code</font></div>
            </td>
            <td valign="top" width="43%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(206)
                623-7612</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="80%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Not
                Applicable</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="80%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
                name or former address if changed since last
                report)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions (see General Instruction A.2. below):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font></div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.3; MARGIN-RIGHT: 0pt" align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
          communications pursuant to Rule 14d-2(b) under the Exchange Act </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(17
          CFR
          240.14d-2(b))</font></div>
      </div>
    </div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.3; MARGIN-RIGHT: 0pt" align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
          communications pursuant to Rule 13e-4(c) under the Exchange Act </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(17
          CFR
          240.13e-4(c))</font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
          1.01</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Entry
          Into a Material Definitive Agreement</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      June
      23, 2006, Targeted Genetics Corporation, the International AIDS Vaccine
      Initiative, or IAVI, Columbus Children&#8217;s Research Institute, or CCRI, and The
      Children&#8217;s Hospital of Philadelphia, or CHOP, entered into a Collaboration and
      License Agreement, or the Agreement, in support of the development and
      commercialization of HIV/AIDS vaccines.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Agreement is effective January 1, 2005 and supersedes a previous research
      collaboration entered into among Targeted Genetics, IAVI and CCRI dated February
      1, 2000, as amended on March 14, 2003 by Amendment No. 1, on August 1, 2003
      by
      Amendment No. 2 and on December 2, 2003 by Amendment No. 3, each of which was
      previously filed with the Securities and Exchange Commission.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the Agreement, Targeted Genetics will receive funding from IAVI for
      the
      continued development of HIV/AIDS vaccines for the developing world. The
      Agreement also grants Targeted Genetics rights to utilize the findings from
      this
      IAVI-funded program, or the Collaboration, to develop and commercialize HIV/AIDS
      vaccines for the developed world as well as additional vaccine candidates.
      Under
      the terms of the Agreement, IAVI retains exclusive rights to commercialize
      in
      the developing world any HIV/AIDS vaccine that is developed under the
      Collaboration and is entitled to receive a royalty on income generated by
      Targeted Genetics from the development and commercialization of vaccines
      developed under the Collaboration. Targeted Genetics also granted IAVI a license
      to certain of Targeted Genetics&#8217; intellectual property that would be necessary
      to develop and distribute an HIV/AIDS vaccine developed under the Collaboration
      for the developing world. In connection with the Agreement, Targeted Genetics
      has agreed to issue 25,000 shares of its common stock to IAVI.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Agreement will govern the Collaboration for as long as a vaccine candidate
      is in
      development or has been commercialized as a result of the Collaboration. Due
      to
      the move of the lead investigator of the Collaboration, Philip R. Johnson,
      M.D.,
      from CCRI to CHOP in 2005, CHOP is included as a party to the Agreement.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      copy of
      Targeted Genetics&#8217; press release announcing the Agreement is attached as Exhibit
      99.1 to this current report.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item&#160;9.01</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Financial
      Statements and Exhibits</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;Exhibits:
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="4%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;99.1</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td align="left" valign="top" width="94%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                Release of Targeted Genetics, dated June 28,
                2006</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TARGETED
                GENETICS CORPORATION</font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;H.
              Stewart Parker</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">H.
              Stewart Parker</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dated:
      June 28, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INDEX
      TO EXHIBITS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="bottom" width="13%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><u><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
                </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number</strong></font></u></div>
            </td>
            <td align="left" valign="bottom" width="65%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Description</u></strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
            </td>
            <td align="left" valign="top" width="65%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                Release of Targeted Genetics, dated June 28,
                2006</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v046481_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title></head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><IMG SRC="logo.jpg"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>TARGETED
      GENETICS ENTERS INTO NEW AGREEMENT WITH </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>THE
      INTERNATIONAL AIDS VACCINE INITIATIVE TO SUPPORT ITS </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ONGOING
      HIV/AIDS VACCINE DEVELOPMENT PROGRAM&#160;&#160; </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SEATTLE,
      WA </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      June
      28, 2006 - Targeted Genetics Corporation (Nasdaq: TGEN) announced today that
      it
      has entered into a collaboration and license agreement with the International
      Aids Vaccine Initiative (IAVI), Columbus Children&#8217;s Research Institute (CCRI) at
      Columbus Children&#8217;s Hospital and The Children&#8217;s Hospital of Philadelphia (CHOP)
      in support of the development and commercialization of HIV/AIDS vaccines.&#160;
The new agreement addresses development and commercialization issues consistent
      with the significant progress made in the HIV/AIDS vaccine development program.
      The new agreement supersedes a previous collaboration agreement entered into
      by
      Targeted Genetics, IAVI and CCRI in 2000, when the parties started working
      together on the development of an HIV/AIDS vaccine for the developing
      world.&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      first
      HIV/AIDS vaccine candidate developed under this collaboration has advanced
      to
      human clinical trials.&#160;This HIV/AIDS vaccine candidate is being evaluated
      in clinical trials in Belgium, Germany, India, South Africa, Uganda and Zambia.
      Data from certain of these trials is expected to be announced in the third
      quarter of 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;We
      believe the elements of our new agreement represent an alignment of interests
      of
      all the parties and provide incentive for all parties to share common goals
      related to the development and commercialization of HIV/AIDS vaccines in all
      parts of the world,&#8221; said H. Stewart Parker, President and Chief Executive
      Officer of Targeted Genetics Corporation. &#8220;IAVI is a leader in support of the
      development of HIV/AIDS vaccines for the developing world and a great partner.
      To date, IAVI has substantially funded Targeted Genetics' HIV/AIDS vaccine
      program efforts, significantly exceeding</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IAVI&#8217;s
      initial funding commitment made to the program in 2000.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      IAVI has
      also provided funding to CCRI, CHOP and to conduct human clinical
      trials.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      this new agreement, Targeted Genetics expects to continue to receive significant
      funding from IAVI for the continued development of HIV/AIDS vaccines for the
      developing world. Targeted Genetics also received the rights to utilize the
      findings from the IAVI funded program to develop and commercialize HIV/AIDS
      vaccines for both the developed world and for any additional vaccine candidates.
      Among other rights granted under this agreement, IAVI retains the exclusive
      rights for commercialization in the developing world of any HIV/AIDS vaccine
      that is developed under the collaboration, and will receive a royalty on income
      received by Targeted Genetics from the development and commercialization of
      vaccines. Targeted Genetics will also issue IAVI a small number of shares of
      its
      common stock. The agreement will govern the collaboration for as long as there
      is a vaccine candidate in development or commercialized as a result of the
      program funded by IAVI. In addition, Philip R. Johnson, M.D., who has been
      instrumental to the program since its inception in 2000, joined CHOP in 2005
      from CCRI, and as a result, this new agreement now includes
      CHOP.&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
      the Vaccine Candidates</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      vaccine candidate, tgAAC09, utilizes a recombinant adeno-associated viral vector
      (AAV) that was developed with and manufactured by Targeted Genetics. IAVI is
      funding development, pre-clinical and clinical studies to test the vaccine.
      The
      Targeted Genetics&#8217; AAV manufacturing process utilized for this candidate is
      based on a cell line which was designed by Dr. Philip R. Johnson. As part of
      a
      comprehensive development strategy, a second HIV/AIDS candidate developed in
      this program is slated to go into clinical development. This candidate contains
      a different AAV serotype than is utilized in tgAAC09. Preclinical studies of
      this AAV serotype have demonstrated an ability to elicit an immune response
      at
      lower dose levels. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
      the International AIDS Vaccine Initiative</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IAVI
      is a
      global not-for-profit organization working to accelerate the development of
      a
      vaccine to prevent HIV infection and AIDS. Founded in 1996 and operational
      in 23
      countries, IAVI and its network of collaborators research and develop vaccine
      candidates. IAVI also advocates for a vaccine to be a global priority and works
      to ensure that a future vaccine will be accessible to all who need it.&#160;
IAVI's financial and in-kind supporters include the Bill &amp; Melinda Gates
      Foundation, the New York Community Trust, the Rockefeller Foundation, the Starr
      Foundation, the Governments of the Basque Country, Canada, Denmark, the European
      Union, Ireland, the Netherlands, Norway, Sweden, the United Kingdom, and the
      United States; multilateral organizations such as the World Bank; corporate
      donors including BD (Becton, Dickinson &amp; Co.), Continental Airlines, DHL and
      Pfizer; leading AIDS charities such as Broadway Cares/Equity Fights AIDS,
      Crusaid, Deutsche AIDS-Stiftung, and the Until There's A Cure Foundation; other
      private donors such as the Haas Charitable Trusts; and many generous individuals
      from around the world.&#160;&#160;For more information, see </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.iavi.org</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
      Columbus Children&#8217;s Research Institute</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Columbus
      Children&#8217;s Hospital is a 114-year-old pediatric healthcare network which houses
      the Department of Pediatrics of The Ohio State University College of Medicine.
      Columbus Children&#8217;s&#160;Research Institute (CCRI) at Columbus
      Children's&#160;Hospital ranks among the top 10&#160;in National Institutes of
      Health research awards to freestanding children&#8217;s hospitals&#160;in
      the&#160;United States.&#160; CCRI has nearly 300,000 square feet of dedicated
      research space and is organized into 11 research Centers of Emphasis
      encompassing gene therapy; molecular and human genetics; vaccines and immunity;
      childhood cancer; cell and vascular biology; developmental pharmacology and
      toxicology; injury research and policy; microbial pathogenesis; cardiovascular
      medicine; innovation in pediatric practice and biobehavioral
      health.&#160;&#160;More information is available by calling (614) 722-KIDS or
      through </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.columbuschildrens.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
      The Children's Hospital of Philadelphia</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Children's Hospital of Philadelphia (CHOP) was founded in 1855 as the nation's
      first pediatric hospital. Through its long-standing commitment to providing
      exceptional patient care, training new generations of pediatric healthcare
      professionals and pioneering major research initiatives, CHOP has fostered
      many
      discoveries that have benefited children worldwide. Its pediatric research
      program is among the largest in the country, ranking second in National
      Institutes of Health funding. In addition, its unique family-centered care
      and
      public service programs have brought the 430-bed hospital recognition as a
      leading advocate for children and adolescents. For more information, visit
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">http://www.chop.edu</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
      Targeted Genetics </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Targeted
      Genetics Corporation is a biotechnology company committed to the development
      and
      commercialization of innovative, targeted molecular therapies for the prevention
      and treatment of inflammatory arthritis, HIV/AIDS and other acquired and
      inherited diseases with significant unmet medical need. Targeted Genetics uses
      its considerable knowledge and capabilities in the development and manufacturing
      of gene delivery technologies to advance a diverse product development pipeline.
      Its product development efforts target inflammatory arthritis, HIV/AIDS,
      congestive heart failure, Huntington&#8217;s disease, and hyperlipidemia. To learn
      more about Targeted Genetics, visit its website at </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.targetedgenetics.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Safe
      Harbor Statement under the Private Securities Litigation Reform Act of
      1995:</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>This
      release contains forward-looking statements regar</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ding
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>anticipated
      scientific progress on our research programs,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>
      our
      ability to develop, manufacture, accurately interpret </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>clinical
      results, obtain regulatory approvals</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>
      and
      commercialize any vaccines under the collaboration, the market prospects for
      any
      vaccine, our </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>benefits,
      including royalties, that we expect to derive as a result of this
      collaboration</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>
      and
      other statements about our plans, objectives, intentions and expectations.
      These
      statements, involve current expectations, forecasts of future events and other
      statements that are not historical facts. Inaccurate assumptions and known
      and
      unknown risks and uncertainties can affect the accuracy of forward-looking
      statements. Factors that could affect our actual results include, but are not
      limited to, our ability to obtain, maintain and protect our intellectual
      property, our ability to raise capital when needed, our ability to recruit
      and
      enroll suitable trial participants, the timing, nature and results of research
      and clinical trials, potential development of alternative technologies or more
      effective processes by competitors, and, our ability to obtain and maintain
      regulatory or institutional approvals, as well as other risk factors described
      in Item 1A. Risk Factors in our report on Form 10-K for the year ended December
      31, 2005 and updated in our Form 10-Q for the quarter ended March 31, 2006.
      You
      should not rely unduly on these forward-looking statements, which apply only
      as
      of the date of this release. We undertake no duty to publicly announce or report
      revisions to these statements as new information becomes available that may
      change our expectations.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">#
      #
      #</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investor
      and Media Contact:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stacie
      D. Byars</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Director,
      Communications</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Targeted
      Genetics Corporation</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Phone:
      206.521.7392</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>stacie.byars@targen.com</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X08417AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`V.C`U.C$Q(#$P.C,X
M.C,U``````.@`0`#`````?__``"@`@`$`````0```B:@`P`$`````0```+L`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```$Y@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"P`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DDDE*22224I1L_FW1IH=5)1L_FW?`I*:&<<VIY&(
M!:/2<16]SQ^EEHHW7-<[94YOJ[_T?^#4?4SA<0:QZ/K-#"'O#O0+?TEKVO<W
M](V[]U7Q_/O_`*K?RO7.=9Z&^S,LRW5,R6VD0YS*'V#3Z&S]D9MOI5M;M8]]
M]B(8IV!8LZ[!OBWJWV</-3?7V,FL&PC>7_I]K_4VN97C>^O_`$MBM4.O<VUU
MHV%EP;5#W&:Y9L=8UY]KW;OHK.^KK\BM[L1@!Q:P?;(:*B#_`#===/3NGU-W
MN?[ZWO6N_BS_`(QG_HM)4-0)6>VK8222095))))*4DDDDI__T/54DDDE*222
M24I1L_FW?`J2C9_-N^!246(_GW_U6_E>@Y&6UK8I+;'G^4`!_:AZ,W^??_5;
M^5ZQFYN,R]Y^R765.=`WTV0T`^[TZOLWM_STEAE0WJ[;V",SU"ZQSG5$:[BS
M4GAS?3QZ=W^>COXL_P",9_Z+4L:^F^H/I#@P:!KF.K(C3^:M;6]O^:HOXL_X
MQG_HM)/3>VPDDDDN4DDDDI22222G_]'U5))))2DDDDE*4;/YMWP*DHV1L=,Q
M!XY24UKLS'Q[WBU[6D5"QTD#:QI?NL?N^@S_`,S_`-&LS-P.DY&6X^HW'OW-
M;;4QF&YQLLE]9L^TT9%WK7M_E?05O*_9WJG[;L];TGSZOH[O1C]/]+W>AM_G
M$G_LWUSOV?:=U4SZ/J;O=]CG_";_`.=^S_\`740Q3V]6UM#I6*<+)?DV6U-J
M;NKBDT`N(?Z&V]M>%AV>RWV;:[G_`*Q^C6P+&V-M+2#%K&N`()#@:Y:[;N]R
M!;]AV.]7;LUW;O1B=_N_M?:O_9C^6H9OI?8,W9Z_T7>O]E]/UO4VM^AL]WVK
M9Z?I_P#6TE0^734>+J)(&#_0L?Z?\TS^=_G/HC^=_P"$_?1T&522222E))))
M*?_9_^T*PE!H;W1O<VAO<"`S+C``.$))300E```````0````````````````
M`````#A"24T#[0``````$`!(`````0`!`$@````!``$X0DE-!"8```````X`
M````````````/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>
M.$))30/S```````)```````````!`#A"24T$"@```````0``.$))32<0````
M```*``$``````````3A"24T#]0``````2``O9F8``0!L9F8`!@```````0`O
M9F8``0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````
M!@```````3A"24T#^```````<```_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@`````_____________________________P/H```X0DE-
M!`````````(``3A"24T$`@``````!``````X0DE-!`@``````!`````!```"
M0````D``````.$))300>```````$`````#A"24T$&@`````#/0````8`````
M`````````+L```(F````!`!L`&\`9P!O`````0``````````````````````
M```!``````````````(F````NP`````````````````````!````````````
M`````````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P``
M``$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`
M`````````$)T;VUL;VYG````NP````!29VAT;&]N9P```B8````&<VQI8V5S
M5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N
M9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L
M:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L
M:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0``
M``0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N
M9P```+L`````4F=H=&QO;F<```(F`````W5R;%1%6%0````!````````;G5L
M;%1%6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585```
M``$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585```
M``$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D
M969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````
M!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4
M>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E
M=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T
M<V5T;&]N9P``````.$))3001```````!`0`X0DE-!!0```````0````".$))
M300,``````4"`````0```(`````L```!@```0@````3F`!@``?_8_^``$$I&
M248``0(!`$@`2```_^T`#$%D;V)E7T--``+_[@`.061O8F4`9(`````!_]L`
MA``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,
M#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1
M"``L`(`#`2(``A$!`Q$!_]T`!``(_\0!/P```04!`0$!`0$``````````P`!
M`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"
M!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%
M!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C
M<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5)))
M)2DDDDE*4;/YMT::'524;/YMWP*2FAG'-J>1B`6CTG$5O<\?I9:*-US7.V5.
M;ZN_]'_@U'U,X7$&L>CZS0PA[P[T"W]):]KW-_2-N_=5\?S[_P"JW\KUSG6>
MAOLS+,MU3,EMI$.<RA]@T^AL_9&;;Z5;6[6/??8B&*=@6+.NP;XMZM]G#S4W
MU]C)K!L(WE_Z?:_U-KF5XWOK_P!+8K5#KW-M=:-A9<&U0]QFN6;'6->?:]V[
MZ*SOJZ_(K>[$8`<6L'VR&BH@_P`W773T[I]3=[G^^M[UKOXL_P",9_Z+25#4
M"5GMJV$DDD&522222E))))*?_]#U5))))2DDDDE*4;/YMWP*DHV?S;O@4E%B
M/Y]_]5OY7H.1EM:V*2VQY_E``?VH>C-_GW_U6_E>L9N;C,O>?LEUE3G0-]-D
M-`/N].K[-[?\])894-ZNV]@C,]0NL<YU1&NXLU)X<WT\>G=_GH[^+/\`C&?^
MBU+&OIOJ#Z0X,&@:YCJR(T_FK6UO;_FJ+^+/^,9_Z+23TWML))))+E))))*4
MDDDDI__1]522224I))))2E&S^;=\"I*-D;'3,0>.4E-:[,Q\>]XM>UI%0L=)
M`VL:7[K'[OH,_P#,_P#1K,S<#I.1EN/J-Q[]S6VU,9AN<;+)?6;/M-&1=ZU[
M?Y7T%;ROV=ZI^V[/6])\^KZ.[T8_3_2]WH;?YQ)_[-]<[]GVG=5,^CZF[W?8
MY_PF_P#G?L__`%U$,4]O5M;0Z5BG"R7Y-EM3:F[JXI-`+B'^AMO;7A8=GLM]
MFVNY_P"L?HUL"QMC;2T@Q:QK@""0X&N6NV[O<@6_8=CO5V[-=V[T8G?[O[7V
MK_V8_EJ&;Z7V#-V>O]%WK_9?3];U-K?H;/=]JV>GZ?\`UM)4/ETU'BZB2!@_
MT+'^G_-,_G?YSZ(_G?\`A/WT=!E4DDDDI22222G_V3A"24T$(0``````50``
M``$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D
M`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``W`"X`,`````$`.$))300&
M```````'``8````!`0#_X1)(:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+P`\/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"<_/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB0U(B/SX*/'@Z
M>&%P;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX87!T:STG6$U0
M('1O;VQK:70@,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\<F1F.E)$1B!X
M;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N
M,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z,61B9#AD9C0M
M93!F8BTQ,61A+3@P.30M.&4P-C)A8V-C861A)PH@('AM;&YS.GAA<$U-/2=H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ1&]C
M=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z,61B9#AD9C(M93!F8BTQ
M,61A+3@P.30M.&4P-C)A8V-C861A/"]X87!-33I$;V-U;65N=$E$/@H@/"]R
M9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M971A/@H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X
M<&%C:V5T(&5N9#TG=R<_/O_N``Y!9&]B90!D0`````'_VP"$``("`@("`@("
M`@(#`@("`P0#`@(#!`4$!`0$!`4&!04%!04%!@8'!P@'!P8)"0H*"0D,#`P,
M#`P,#`P,#`P,#`P!`P,#!00%"08&"0T*"0H-#PX.#@X/#PP,#`P,#P\,#`P,
M#`P/#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`+L")@,!$0`"
M$0$#$0'_W0`$`$7_Q`&B````!P$!`0$!```````````$!0,"!@$`!P@)"@L!
M``("`P$!`0$!``````````$``@,$!08'"`D*"Q```@$#`P($`@8'`P0"!@)S
M`0(#$00`!2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O`D<H+Q)4,T4Y*B
MLF-SPC5$)Y.CLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5U
MA96EM<75Y?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I
M.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ$0`"`@$"`P4%!`4&!`@#`VT!
M``(1`P0A$C%!!5$382(&<8&1,J&Q\!3!T>$C0A528G+Q,R0T0X(6DE,EHF.R
MP@=STC7B1(,75),("0H8&28V11HG9'15-_*CL\,H*=/C\X24I+3$U.3T976%
ME:6UQ=7E]4969G:&EJ:VQM;F]D=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@Y
M25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`/OYBKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK"M
M4\_^5-(U2[T:\U%_TE8)$][:Q032F(3J6BY%$(^(`D;Y(0)<3)KL6.9@3N.>
MQZ\D#_RL[R=_RVW/_2'<?]4\/`6'\HX>\_(_J=_RL[R=_P`MMS_TAW'_`%3Q
MX"O\HX>\_(_J=_RL[R=_RVW/_2'<?]4\>`K_`"CA[S\C^IW_`"L[R=_RVW/_
M`$AW'_5/'@*_RCA[S\C^IW_*SO)W_+;<_P#2'<?]4\>`K_*.'O/R/ZG?\K.\
MG?\`+;<_](=Q_P!4\>`K_*.'O/R/ZG?\K.\G?\MMS_TAW'_5/'@*_P`HX>\_
M(_J=_P`K.\G?\MMS_P!(=Q_U3QX"O\HX>\_(_J=_RL[R=_RVW/\`TAW'_5/'
M@*_RCA[S\C^IW_*SO)W_`"VW/_2'<?\`5/'@*_RCA[S\C^IW_*SO)W_+;<_]
M(=Q_U3QX"O\`*.'O/R/ZG?\`*SO)W_+;<_\`2'<?]4\>`K_*.'O/R/ZG?\K.
M\G?\MMS_`-(=Q_U3QX"O\HX>\_(_J=_RL[R=_P`MMS_TAW'_`%3QX"O\HX>\
M_(_J=_RL[R=_RVW/_2'<?]4\>`K_`"CA[S\C^IL?F;Y/)H+RY)_YA+C_`*IX
M\!7^4</>?D?U,NT76=,\PZ38:WHUVM]I>IPK/8W:AE$D;="`P!'TC(D4:+E8
M<L<L!.!L'DFF!L=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BK__0^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O./+I/\`RL+\R]^D>B4_Z1Y<G+Z0X&G_`,9R
M_P";]Q>B5/CD'/?/'YU_G'YW_*:/4M;T[\J+SSEY)T+1CJWF'S1;ZA9VPM`C
M.)$]&>5))"J*&^!3URR$`>N[INTNT<^D)E'$9P$;,K`KX<T__)[\Q_.WYC6E
M[JGFC\L[K\OM)DMK.[\M7=S?6MX=0BN59G8"VDD]/A1=GH=\$XB/)N[-UN;5
M1,LF/@!`(W!N_<C_`#?^<_DSR1Y^\C?EOKMS+#YC_,)9F\OJ%_=$0;-ZCD@+
M4["O4[8B!(MEJ>T\6GSPPROBGR[OFSKS7YDL/)WEGS!YKU8R?HORW87&I:D8
MAR<06T9DD*CN0JG;(@6:<O49XX,4LDN402?<'BGD#_G)_P#+7\P=;T7R]9QZ
MYH&I>9X9)O*YUO2KNQ@U)8@&<6MQ-&L4A`8;!JGMEDL1BZK1=OZ;53C`<43+
MZ>($<7]4\B]2_,'\QO*7Y7^79?-'G/5?T9I:2I;VX2.2>>YN)=HX+>")7DED
M<]%52>_0'*XQ,N3L=9K,6DAQY30^\]P\V,_EI^=7E+\TKO5],T2SUS2=:T%(
MY=6TC6]*O-.EB24_NS6XB1&Y=:`U]LE/&8N-H.U<6L)C$2$AS$HF)^T)!^8/
M_.1'E/\`+KS@/(^IZ#YDUG7CIL>K+;:%I=QJ?^ARR/$LK"V60H"\3#X@.F&.
M/B%VU:WMK'I<OA2C.4JOT@RV^#T?3_/-EJ'D.W\_II>JP6%QIWZ271Y[62/4
M52E?3:U8!Q)_DTKD3'>G-AJQ+!XU&JNJ]7R>(>6_^<M/(?FGS#;^5]-\K^<U
MU>2XM[>]@N-"O8A9-=+RB-V7C'HAE^(%Z5&XR9Q$"[#JL/M%ARY!C$)W8'TG
M:^_N>F_FO^<?EC\GK+0KWS-;:E>+YBOCIVF6^EVSW<\EQQY*BPQ@NQ;H*`Y&
M$#+DYW:7:F+0B)R`GB-"A9M'_EM^9NF_F;8ZA?Z9H6O:#'IUQ]6E@U[3I]-F
M=J5JD=PB,5]Z4P2CPMFAU\=7$D1E&OYP(^]YEYD_YRK_`"T\I>;/,?E/6[3S
M$DOE&:.+S)K%GI%W>V-D)03&\\UM'($5@":M3;?)C$2+<#+[0:?%FEBD)>D[
MD`D#WD<GT/I>J6&M:;8:QI5W'?Z9JEO'=Z?>PMRCEAF4/&ZGN&4@Y413NL>2
M.2(E$V"+".KL?D<6;`/RG)/Y<^4234_4%W_V39/)]1<'LS_%H>YZ'D'.=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_
M`/_1^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*O./+G_DPOS+_`.,>B?\`4-+DY?2'`T_^,Y?\W[B]#R#GO$O^<DM(
MU;S!^0OYL:%H.F76LZUK'ER\M-+TNSC::>>>5.*(B*"22<E#F'6]L0E/1Y8Q
M!),3L!9^3,/RLM+RP_+?R/8ZA:3:??6FBV<5W97*&.6*1(@&1T.X(/4'&?U%
MM[.B8Z;&)"B(C8OA#\VORP_.7\SO-WYQ?F/H^B1:<GE&?3;/\O-)UBQN)-4N
MH]#FBO)Y-(E25%C2[GMZ;QOS#;4KF3"<8@"^?XW>/[1T&KUF;-J(PK@($1(&
MSP4;AW61W&^C["_,%M=\Y?\`./7G%H]`O$\S>9?(MZ/\,&%UNA?7.GM6U]$C
MES]1N('6N40H3'O>FUW'J.SLGI/%+&=JWLQY5SYOD_\`*+\I?.OE;\P/R$U/
MSS!YK\Z>6(/*<OZ"M]5BYCR?KP">NLR0Q1^G'+'Q6,R5(*FI.U+LDP1*GG>R
M^S,N'-II9A.<1#:Q_=SZW0V%<K>^?\Y'>5O-EY=_E/\`F'Y5\N2^=S^5/F8Z
MUJ_DF!U6:\M9;2>U:2V5@P>:$RAU6E33;*<='8FG>]M8LMX\V.!R>'*S$=17
M,=Y"0_\`./\`JWYOZW^8?GV_\R?XN7\JS90_X47SMI]MIFI_I"67U)D6".W@
ME:*)#P5GKL!O7)Y1$`55N+V+DU>34Y)9./PJ'#QQ$3?7H#Y;O//SQT'S!_T,
M6/-"Z3^9L?EIO(MGI8US\O;5I7DO([Z[F>WG;TI`5"2*=J4J<EB/HZ<^K@=L
MXI_R@,E9N'PP+Q#K9-'8OMGR9K\GF?RUI&NRZ)JGEU[^$,='UJ!K:_AI\-)X
MF`*L:5H<HD*+UNDS'-BC,Q,;Z2%2^(>-_EIH^O6/Y[_\Y$ZQJ&DZA9:)Y@E\
MMMH.IW$3I;7?U/31!,87;X6X/\.V2E](==HH3&MU$B"`>&B0:-#H>K`O^<P/
M+GF37[#\J)_+^B^9-6CT/S;#?ZQ<>58&GU*TMHU!::$!7`84VJ.N6:>0%WW.
ML]JM/ERQPF$9RX9V>`7(#O#UW\D?,DNI^7CH$FA>>[)/+")"FO>?;1K;4-1]
M5G8N6*1ARO0D#I3*\@HWM\':=CZ@SQ^'PY!P=<@J4OUOF:_U3SQY*_,'_G)R
MTM/R?\V^<#^:4EE:^4KNQL6&G3%;.>UD::[<&.-%:4$L=J9=0E&.X%.@EESZ
M;4ZH#!.?BD"-#T\B-Y<NKZH_(CR)JOY9_E#Y"\CZ[=B\UC0-)@@U)T;DB3%>
M3Q(U358R>`(Z@91.7$;>F[)TDM)I88IFR!O^/)ZWV/R.0=BP#\I__)<>4?\`
MF`7_`(DV3R?47![,_P`6A[GH>0<YV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_TOOYBKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKSCRY_Y,+\R_P#C'HG_`%#2
MY.7TAP-/_C.7_-^XO0\@Y[S#4;KSMJOF_5='\O\`F+3]"T_2K&VE*7.FF]DD
MEF=P6Y_6(:"B]*9,4!NZW)+/DS2A"0B`!SC?Z0K_`*#_`#1_\N!H_P#W`3_V
M6XW'N9>#J_\`58_Z3_CSOT'^:7_EP=(_[@)_[+<;CW+X.K_U6/\`I/\`CSOT
M'^:/_EP-(_[@)_[+<;CW+X.K_P!5C_I/^/._0?YI?^7`TC_N`M_V6XW'N7P=
M7_JL?])_QYWZ"_-+_P`N!I'_`'`&_P"RW&X]R^#J_P#58_Z3_CSOT'^:7_EP
M-(_[@+?]EN-Q[E\'5_ZK'_2?\>=^@_S2_P#+@:1_W`6_[+<;CW+X.K_U6/\`
MI/\`CSOT'^:/_EP-(_[@)_[+<;CW+X.K_P!5C_I/^/._0?YH_P#EP-(_[@)_
M[+<;CW+X.K_U6/\`I/\`CSOT'^:/_EP-(_[@)_[+<;CW+X.K_P!5C_I/^/._
M0?YH_P#EP-(_[@)_[+<;CW+X.K_U6/\`I/\`CRG-H_YI1PS2#\P-(K'&S#_<
M"W4`G_ENQN/<@XM6!_>Q_P!)_P`>9-Y.U6\UKRYIVH:@8VO9`Z7,D2\$=XG*
M%U0EN(:E:5-,$A1<G2999,8E+FR;L?D<BY#`/RG_`/)<>4?^8!?^)-D\GU%P
M>S/\6A[GH>0<YV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*O_]/[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J\X\N?^3"_,O\`XQZ)_P!0TN3E](<#3_XSE_S?
MN+T/(.>P#2/_`"8?FS_MG6/_`!.7)GZ0X&+_`!F?N'Z6?Y!SW8JLD<QQO((V
ME**6$24Y-3LM2!4^YQ030?E_Y]D_Y^%>;/,-[J&@Z1!Y+T))I%TG0[&XM&*0
MAJ*99C(&D9@*[].V9<1B'5X#62[>S9"80,8]`#'\%A?^&_\`GX__`-76X_Z2
M+/\`ZJY*\7X#B>#[0?TO],'?X;_Y^/\`_5UN/^DBS_ZJXWB_`7P?:#^E_I@B
M;/1/^?D%E>6EZM^UR;2591;7$UF\,G$UX2*9=U/<8#X3*&/V@B0:.WG%^G/Y
M>:UYK\P>4M*U'SOY5?R=YJ*&+6M$,T<\:S)LTD$L3,&C?JM:'Q&8LP`=MWOM
M#FRY<0EEAP3ZC;[*O9FN1<MV*NQ5#W?^\EU_QAD_XB<6,N18A^77_*(Z;_QD
MN/\`D\^2GS<70?W(^/WLW['Y'(N8P#\I_P#R7'E'_F`7_B39/)]1<'LS_%H>
MYZ'D'.=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BK__4^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*O./+G_DPOS+_`.,>B?\`4-+DY?2'`T_^,Y?\W[B]#R#G
ML`TC_P`F'YL_[9UC_P`3ER9^D.!B_P`9G[A^EG^0<]V*O"/^<A--_.[5?)<%
MI^1>HV>F^9)+V,:E-<M$DIM#]KT7G!C!KUKO3IOEF,Q!]3I>W,>NG@`T9`G>
M]]WE>SXH_P"5>?\`/P__`*G&'_I-TW_FG+^+$\C^1]H_]4^V+O\`E7G_`#\0
M_P"IQA_Z3=-_YIQXL2_D?:/_`%3[8N_Y5Y_S\0_ZG&'_`*3=-_YIQXL2_D?:
M/_5/MB[_`)5Y_P`_$/\`J<8?^DW3?^:<>+$OY'VC_P!4^V+O^5>?\_$/^IQA
M_P"DW3?^:<>+$OY'VC_U3[8OJ?\`YQX3_G)?11>^7OSSTVSUBQ^*?2?.%O>V
MKW"%CO;SPPD<A_*RCIURG)P'>+TO88[3QW#6`$=)6+]Q`?4^5/1NQ5#W?^\E
MU_QAD_XB<6,N18A^77_*(Z;_`,9+C_D\^2GS<70?W(^/WLW['Y'(N8P#\I__
M`"7'E'_F`7_B39/)]1<'LS_%H>YZ'D'.=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_`/_5^_F*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O./+G_DPOS+_`.,>
MB?\`4-+DY?2'`T_^,Y?\W[B]#R#GL`TC_P`F'YL_[9UC_P`3ER9^D.!B_P`9
MG[A^EG^0<]V*NQ5\'?F+^5/_`#EK%YNU2;\M_P`W+[4/*-Z_UC38+Z\M;>>T
MY_:MS6U?F%/1JC8TIMET90K</)ZW0=J#*?!S$P/*R`1Y<F#_`/*L?^<[_P#R
MY3_]Q6T_[(L/%#N<7\CVU_JOVC]3O^58_P#.=_\`Y<I_^XK:?]D6/%C[E_(]
MM?ZK]H_4[_E6/_.=_P#Y<I_^XK:?]D6/%C[E_(]M?ZK]H_4[_E6/_.=__ERG
M_P"XK:?]D6/%C[E_(]M?ZK]H_4T?RP_YSN.W_*RW'N-5M/\`LBQXH=R_D>VO
M]5^T?J?:OY-:=^9NE>1=/LOS:U.WU;S?$\@N;J!EDK%R/I\Y$5%=J;DA1E4J
MO9Z?LV&HAA`U!N;U7(N>A[O_`'DNO^,,G_$3BQER+$/RZ_Y1'3?^,EQ_R>?)
M3YN+H/[D?'[V;]C\CD7,8!^4_P#Y+CRC_P`P"_\`$FR>3ZBX/9G^+0]ST/(.
M<[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7_];[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J\X\N?^3"_,O\`XQZ)_P!0TN3E](<#3_XSE_S?N+T/(.>P#2/_
M`"8?FS_MG6/_`!.7)GZ0X&+_`!F?N'Z6?Y!SW8J[%78J\_\`S,\G:EYV\K7>
ME:'YEO\`RCKT7[_1M;T^4QLDZ@\4E`^W&U:,#\^HP@TXFMT\L^,QC(QET(_'
M)\6+^2?_`#EO0<_S'4-3XN.LW!%?:L&6<47G/Y-[2_U3_9']3?\`RI/_`)RU
M_P#+D#_N,W'_`%1QXHK_`";VE_JG^R/ZG?\`*D_^<M?_`"Y`_P"XS<?]4<>*
M*_R;VE_JG^R/ZE2'\CO^<K[B>&"Z_-%K.UFD5+J\CU:=WBC)H[HGH_$P%2!W
M./%%([,[1)HY*'O/ZGW_`*592:;I>FZ=+>2ZA+86L-O+J$W][.T:!6E?K\3D
M5.5%ZK''AB`3=#FC\6:'N_\`>2Z_XPR?\1.+&7(L0_+K_E$=-_XR7'_)Y\E/
MFXN@_N1\?O9OV/R.1<Q@'Y3_`/DN/*/_`#`+_P`2;)Y/J+@]F?XM#W/0\@YS
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5?_U_OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKSCRY_Y,+\R_P#C'HG_`%#2Y.7TAP-/_C.7_-^XO0\@Y[`-(_\`
M)A^;/^V=8_\`$Y<F?I#@8O\`&9^X?I9_D'/=BKL5=BKL5=BKR[\TO(VO^<M)
MA_PIYKN_*GF"Q8M:7,<TJ6TRGK'.D9W'@0*C"#3A:W33S1]$C&0^7Q?/I_)'
M_G(BFWYN6G*FW[^_I7)6'5?R;K?]5'VOIW\OO+&J>4_+%EI6N:]<>9-:WEU3
M59Y'<-*YJ5BYDD(O1>].N1)=SI,,L6,1E+B/4LVP.2[%4/=_[R77_&&3_B)Q
M8RY%B'Y=?\HCIO\`QDN/^3SY*?-Q=!_<CX_>S?L?D<BYC`/RG_\`)<>4?^8!
M?^)-D\GU%P>S/\6A[GH>0<YV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\`_]#[^8J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J\X\N?^3"_,O\`XQZ)_P!0TN3E
M](<#3_XSE_S?N+T/(.>P#2/_`"8?FS_MG6/_`!.7)GZ0X&+_`!F?N'Z6?Y!S
MW8J[%78J[%5"ZNK:RMY;N\N([6UMU+SW$K!$11U+,=@,42D(BSR?/6M?\Y+^
M2M.U"6RTZSN];@@^%]0@HD3,#N$+`\A[C;#PNKR=KXHF@"4J_P"AI/+'_4NZ
MA_R,3^F'A:_Y9A_-*(M?^<H/*,UU;Q76C7]E;2N$FO&97$0)IR90*D#O[8.%
M,>V,9.X(?1]C?6>I6EO?Z?<QWEE=H)+:ZB8,CH>A!&!VT9"0L;@HK%DA[O\`
MWDNO^,,G_$3BQER+$/RZ_P"41TW_`(R7'_)Y\E/FXN@_N1\?O9OV/R.1<Q@'
MY3_^2X\H_P#,`O\`Q)LGD^HN#V9_BT/<]#R#G.Q5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]'[^8J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J\X\N?^3"_,O\`
MXQZ)_P!0TN3E](<#3_XSE_S?N+T/(.>P#2/_`"8?FS_MG6/_`!.7)GZ0X&+_
M`!F?N'Z6?Y!SW8J[%78JE>L:UI>@6,VI:Q>QV-G`*O+(?P`ZDG%A/)&`N1H/
M"-3_`#T\L7XFLY?+5WJ.G\OA]9>(?B=B4H<-.NGVC"6W"2$C_P"5K>0__+?*
M/^>2?\T8::_SF+^8[_E:_D3_`,M\O_(I/^:,5_.8OYCO^5K^0^_Y?K3O^Z3_
M`)HQI?SF+^8]S\A:U;Z[H*7EEH,WE^Q$C):6DJ\`Z]>:#;X221TP%V&FR"<+
M`H,TP.0A[O\`WDNO^,,G_$3BQER+$/RZ_P"41TW_`(R7'_)Y\E/FXN@_N1\?
MO9OV/R.1<Q@'Y3_^2X\H_P#,`O\`Q)LGD^HN#V9_BT/<]#R#G.Q5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]+[^8J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J\
MX\N?^3"_,O\`XQZ)_P!0TN3E](<#3_XSE_S?N+T/(.>P#2/_`"8?FS_MG6/_
M`!.7)GZ0X&+_`!F?N'Z6?Y!SW8J[%6/Z_P"9]'\MVQGU*Y"R$?N+1/BED/8!
M?XG;%JR9HXQN\JO/S2T+4/3-]Y7:\]$DP^N(WXU\*UIAIPY:R,N<;0?_`"L/
MRI_U)<7_`"*BQI'YG'_,=_RL/RI_U)<7_(J+&E_,X_YCO^5A^5/^I,B_Y%18
MTOYG'_,9MY3N](\T^M/'Y.@L;&#9;R:&.DCU^R@`J:>/3%OPF.3?AH/2@`H"
MJ`JJ`%4;``=`,#EMXJA[O_>2Z_XPR?\`$3BQER+$/RZ_Y1'3?^,EQ_R>?)3Y
MN+H/[D?'[V;]C\CD7,8!^4__`)+CRC_S`+_Q)LGD^HN#V9_BT/<]#R#G.Q5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_
M_]/[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J\X\N?^3"_,O\`XQZ)_P!0TN3E](<#3_XSE_S?N+T/(.>P#2/_`"8?
MFS_MG6/_`!.7)GZ0X&+_`!F?N'Z6?Y!SW8J\`U3\_M*T_4;RQ@\MWMXEG,\+
M7!DCBY-&Q5J(VX%1WPTZV?:48R($2:26;\^]#N)!+<>199Y0.(DDDMV:GA4@
MG#36>T8GG#[E/_E>OEW_`*D!O^"MO^:<:7^48?S/N=_RO7R[_P!2`W_!6W_-
M.-+_`"C#^9]R<Z!^:MGYFU.#2='_`"V>XNIMW<M;".).[NW'8#\<%,\>L&27
M#&'W/=1I>FT%=-M`:;CT8^OW8'8\$>X(N***%!'#&D,:_9C10JCY`;8I`I4Q
M2[%4/=_[R77_`!AD_P"(G%C+D6(?EU_RB.F_\9+C_D\^2GS<70?W(^/WLW['
MY'(N8P#\I_\`R7'E'_F`7_B39/)]1<'LS_%H>YZ'D'.=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__U/OYBKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKSCRY_Y
M,+\R_P#C'HG_`%#2Y.7TAP-/_C.7_-^XO0\@Y[`-(_\`)A^;/^V=8_\`$Y<F
M?I#@8O\`&9^X?I9_D'/=BKRS\RO-DGD*P@UF+R0GF33G?AJ-Q"\<3V[,?A9E
M,3E@QVJ.F$.%J\_@#BX.(/%/^AE-,VI^6+FI``$\>Y/3_CWQIU_\KQ_U/\?)
M]%>4+JZ\P:/%JNM>38?*\MR>5MILK1SS>D>C2<8T"D_R]L2[7!(Y(\4H</DR
MC]'Z?_RP6W_(I/Z8&[A'<JQ6UM`2T%M%"S"C-&BJ2/F`,4@`<E?%+L5=BKL5
M0]W_`+R77_&&3_B)Q8RY%B'Y=?\`*(Z;_P`9+C_D\^2GS<70?W(^/WLW['Y'
M(N8P#\I__)<>4?\`F`7_`(DV3R?47![,_P`6A[GH>0<YV*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_U?OYBKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKSCRY_Y
M,+\R_P#C'HG_`%#2Y.7TAP-/_C.7_-^XO0\@Y[`-(_\`)A^;/^V=8_\`$Y<F
M?I#@8O\`&9^X?I9_D'/=BJR0QK&[3%1$JDREZ<0HZUKM3%2E(O\`RZ""+S3`
M1T(DA_KC37QP[PK_`*9T?_J[67_21'_S5BGQ(]X58=2TZYD$-OJ%M<2M4K%'
M,CL:;F@!)Q2)Q/(HW%D[%78J[%78JA[O_>2Z_P",,G_$3BQER+$/RZ_Y1'3?
M^,EQ_P`GGR4^;BZ#^Y'Q^]F_8_(Y%S&`?E/_`.2X\H_\P"_\2;)Y/J+@]F?X
MM#W/0\@YSL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5?_];[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J\X\N?^3"_,O\`XQZ)_P!0TN3E](<#3_XSE_S?N+T/
M(.>P#2/_`"8?FS_MG6/_`!.7)GZ0X&+_`!F?N'Z6?Y!SW8J\A_-/2&\Z:4?+
M%G^85KY0MI&(UP12P_69DIM">1JBGO3J-CMA&SK];#QH\`R"/?WOFT?\XP^7
M!L/S;M]O\NV_KDN)U'\C8_\`5?N;_P"A8O+G_EVX/^#MOZX\2_R-#_5?N3+1
M_P#G'NQ\O:I9:UHGYSQ6&J:?();6Y1[;J.JL*[JW0@[$8\3/'V5''(2CFHCW
M/KZV\PZ,MM`MWYBTN6Z6-1<2I<Q!6<#XF`Y;5.],@[^.:%;R%^].H9X;F*.X
MMIDN()EY13Q,'1E/=6%01BV`@BPJXI=BKL50]W_O)=?\89/^(G%C+D6(?EU_
MRB.F_P#&2X_Y//DI\W%T']R/C][-^Q^1R+F,`_*?_P`EQY1_Y@%_XDV3R?47
M![,_Q:'N>AY!SG8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J_P#_U_OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKSCRY_Y,+\R_P#C'HG_`%#2Y.7TAP-/_C.7
M_-^XO0\@Y[`-(_\`)A^;/^V=8_\`$Y<F?I#@8O\`&9^X?I9_D'/<-L5?`/G7
M_G%33Y?-&L:@WYL1Z+%K-S+?VUAJ#.9E69RS#D9TY*&)`H-AMEHGY/*:GL./
MB$^+5[T?[6+?]"J:9_Y>W3?O?_LIP\9[FC^0X_ZL/Q\7?]"J:9_Y>W3?O?\`
M[*<>,]R_R''_`%8?CXN_Z%4TS_R]NF_>_P#V4X\9[E_D./\`JP_'Q=_T*II?
M_E[=-^]_^RG'C/<O\AQ_U8?CXOI'\E/+A_*G3[W0=2_-;2?-'EZ5O6TVTD8)
M+:2'[821IGJC?RGIVIOD);]'<=FXORD3$Y1*/3R^U]!V&LZ1JK2)IFJ6NH/"
M`94MY5D*@]R%)ID:=M#+"?TD%,\#8[%4/=_[R77_`!AD_P"(G%C+D6(?EU_R
MB.F_\9+C_D\^2GS<70?W(^/WLW['Y'(N8P#\I_\`R7'E'_F`7_B39/)]1<'L
MS_%H>YZ'D'.=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BK__T/OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKSCRY_Y,+\R_P#C'HG_`%#2Y.7TAP-/_C.7_-^X
MO0\@Y[`-(_\`)A^;/^V=8_\`$Y<F?I#@8O\`&9^X?I9_D'/=BKQ;\Y_R-\I?
MG9I6GV6OO<:=J.D3>KI>N63%)XE/]Y'4$<E<;$')1F8NL[3[*Q:^($]B.1'-
M\K:A_P`X6_E'I%R+/5?S4OM-NR@D%O=7:0N4-0&`>45&V6C*3T=!/V:TN,U+
M*0?,_M07_0G_`.27_EY)?^XC#_U6Q\27<P_T/:+_`%;[1^MW_0G_`.27_EY)
M?^XC#_U6Q\27<O\`H>T7^K?:/UN_Z$__`"2_\O)+_P!Q&'_JMCXDNY?]#VB_
MU;[1^MW_`$)_^27_`)>27_N(P_\`5;'Q)=R_Z'M%_JWVC];,?(7_`#CW^7'Y
M:^9['S7Y3_/.6RU&T(6XA>^@D@NK?D"\$\;3493^!WP&1/,.1I.R=-I<@R8\
M]$>8W'<=WV[INKZ3K,4D^D:G:ZI!$_"66TF295:E>+%":&AZ9413U./+#(+B
M0?<;3'`V(>[_`-Y+K_C#)_Q$XL9<BQ#\NO\`E$=-_P",EQ_R>?)3YN+H/[D?
M'[V;]C\CD7,8!^4__DN/*/\`S`+_`,2;)Y/J+@]F?XM#W/0\@YSL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_1^_F*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MO./+G_DPOS+_`.,>B?\`4-+DY?2'`T_^,Y?\W[B]#R#GL`TC_P`F'YL_[9UC
M_P`3ER9^D.!B_P`9G[A^EG^0<]V*NQ5\]?GQ_P`XV^1/S]M=(_Q&9=)UK1)2
M;'S!9(AN/0;[<#\MG4TVK]GMU.68\A@Z/MGL#!VH!Q[2CU'.NY\V_P#1-_\`
M++_J<];_`.1,&6_F3W.@_P!`6E_U27V._P"B;_Y9?]3GK?\`R)@Q_,GN7_0%
MI?\`5)?8PK7_`/G";_G'3RIJ"Z3YF_.230=3:%;A+"_EL[>5H6)59`LC`E25
M(J-JC)#/(\@XF;V1[.PRX<F<Q/.C7))?^A2O^<5?_+^VW_298?\`->'QI]S5
M_H7[+_Y2/M")LO\`G#S_`)Q@U*\MM/T_\]8KR^O)!%:6D-S8O)([=%50]23X
M8/&GW,H>RO9DR`-19/F'WK^1_P"1GE#\AO+%WY;\J/<W1U2Z^NZSJ5VY+W$X
M4(K<*E4`0`47;:N8\YF9LO9]D=CX>S,1QX[-FR3U/Z'M&0=LA[O_`'DNO^,,
MG_$3BQER+$/RZ_Y1'3?^,EQ_R>?)3YN+H/[D?'[V;]C\CD7,8!^4_P#Y+CRC
M_P`P"_\`$FR>3ZBX/9G^+0]ST/(.<[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%7_]+[^8J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J\X\N?^3"_,O\`XQZ)_P!0
MTN3E](<#3_XSE_S?N+T/(.>\H_3^C:!^87F;]-:A%I@N=-L6MVN#P$@#R@\"
M>M.],LHF(IU?CPQ:F?&:L#G\62?\K$\D?]3-8?\`(U?ZY'@+D_G\'\\?-W_*
MQ/)'_4S6'_(U?ZX\!7\_@_GCYN_Y6)Y(_P"IFL/^1J_UQX"OY_!_/'S=_P`K
M$\D?]3-8?\C5_KCP%?S^#^>/F[_E8GDC_J9K#_D:O]<>`K^?P?SQ\W?\K$\D
M?]3-8?\`(U?ZX\!7\_@_GCYOG7\^_P`J/R#_`.<A8=#/F[S)#INJ^7W<V.O:
M:]LMV89/M0.\L<G*.NX!Z$DBA)RS&90Z6Z7M?1:+M(#CR<)'6)%UW>Y\W?\`
M0B7_`#C!_P"70UC_`)'Z?_V2Y;XTOYH=#_H3[/\`^4B?S'ZF=?EI_P`XE_\`
M.,_Y9^=M$\\V?G>ZUW4/+\C3Z;9:E-9FW68J560K%#&Q*UJ-Z5R,\DI"J`<S
M0=@=GZ3,,HS2E721%?<^X?\`E8GDC_J9K#_D:O\`7*.`O6?G\'\\?-W_`"L3
MR1_U,UA_R-7^N/`5_/X/YX^:C<_F%Y):VN0/,U@289*#U5_E/OCP%C+78*/K
M'S7?ER&_P?I3%&02F:2/D"I*/*S*U#V(-1C/FG0?W(_'5F_8_(Y%S&`?E/\`
M^2X\H_\`,`O_`!)LGD^HN#V9_BT/<]#R#G.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__3^_F*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O./+G_DPOS+_`.,>
MB?\`4-+DY?2'`T_^,Y?\W[B]#R#GOGK\V_SB7RAYI\K_`)=^4?)"_F3^:'FR
M&2ZT_P`NM/'9P6MA":27EY=R1RB*,$$#X34@Y9"%BR:#I>T>TAARPPXX>)EE
MTNJC_.)[D]_*[S)YQ\UR>8K+\POR@A_+J_T&:.*WG2[AU&SU$2!B7M9E@B+*
ME/BJ.XP2`%4;;=!GRYI3CFP^'P\C=B7NV"7^?/S?\J>0_..G^1&_+_S#YN\R
M:GI4FM6UCY:TF._(LHI5@>22KQ\:2,!AC`R'-CK.T<>FR#'X<IR(NHQ!V>E^
M5+VP\TZ!INO/Y4NO+;:BKN=$UFR2VOH.+LE)X?BXD\:@5Z$9&6QJW-TTXYL8
MGP&-])"B/>'AL7_.2_Y/3:5^:^IC3;Q7_)B5(_.NFMIZ"Y59)/366W2O[U2>
M^V2,"'6X^V-+,9"!OC^H4.^GOM[-HMAH5WY@N-,A6SL["34)T]%.8BCC,K`"
MG7B.F0WMVLC",#,@4!;Q/\NOST\L?F?<>7V\N_E1YRM]#\QQM+8^;M0T*.WT
ML1JA<,]QZK4#4HOP[G+)8S'JZK1=K8]68\&&?#+^(Q'#\[9S^9'G?1_RUL;+
M4KKR#K?FNUN3.;H^7-+2^>TC@0.TMPO).*4.QR,(F75RM?JX:2(D<<I`W],;
MJN])_P`J/S4\L?F_:R:IH'D/7M%T-[:*ZTO7=<TI+.VU"*6M&M'Y/Z@%-^E,
M9Q,>K#L_7X]:.*&.0CT,A0/N9%/YS\J0?F58_E8^C.?,5_H<OF&"X%JAM190
MS+;N6D[-ZC@<:>^"C5MYSXQG&'A]1%\NB%_,O\PO(OY5:7IU_P"8M/>]O-<O
M8]-\N>7=+LUNM1U&[D(`AM;<<2["M3OL,,8F7)AK];@T409BS(T`!9D?(+/R
MT\^>7_S,LM7N;3R3K'E6YT*\.GZKIGF+2ULIX[A5#%5%7#4#`U![XRB8]5T.
MKQZL2J!B8FB)"MV'>=?SS\E>3_-6L^3K7R#YC\[ZQY9L[?4/-*>6M'2^33X+
MI2\)F/-#5U4L``=AAC`D7;BZOM7#I\IQC'*9B+/#&Z#W;1=2MM:T;2-8LH9;
M>SU:S@O+2WN(_1E2*>-9$62,_88!@".QVR!%&G;X<@R0C,;`@'?S3/L?D<#8
MP#\I_P#R7'E'_F`7_B39/)]1<'LS_%H>YZ'D'.=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__4^_F*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O./+G_DPOS+_
M`.,>B?\`4-+DY?2'`T_^,Y?\W[B]#R#GOC;\[_('GS2OS;T3\Z_)/ENX\_V%
MYY7G\D>=_)UA/':ZBEA/))(E[822LJF1&F:JEEZ#?+L<A5'9YGM;1YXZF.IQ
MQ,QPF$HC8T>H*W_G%CR5^8GE[7OS,UGS7I?F?0_*&J26,/Y?:%YQU?\`2NJV
ML4*R_62S!Y51969#3G7;!D(VHLNPM/GA/)+)&48DCA$CQ$!C?_.0WDK7];_/
M'RKYGC\C?F!YE\L:7Y/N-,GU#R!J,6F7<=]+?QW"I+(]Q`9(C&IJM:5PP-1Y
MM/:^FG/5QGX<Y1$*]!HV3?.QL^O_`,O]8O-<\I:+J%_Y:U7RA<M$86\OZVT;
M:A`L!,2&X:)Y$+.JAJAC6N5RYO0Z/(9XHDQ,?(\]N]^9'GW_`)QU_-#5/(/Y
MC>:/*OE;4-/\_:SY]UJTO="`@$VM^4]4-EO(3)QI&UN6CJ:BK>.9)RCETIX7
M+V)J#BGEA$C)+)($;7+'*J^`(^]^FVOVMW=_E_K-A;VSO?W/EZYMH+,@<VF>
MU9%CI6E2Q`ZYC`^I[G-$RT\H@;F)'V/B;_G%/1?-7Y86_EG0-9_*C\TK+6-1
MT^/3=>U+6=2MKKRYI_IGU#):VPO',(9MOAC]LMRD2/-YGV?Q9=)&,)8L@E5$
MDC@&_,"]OD^X?/%M=7GDWS3:6-M)>7ESI=U%:VL5.<DC1L%5:D"I/OE4>8>G
MUL3+!,`62"\__P"<<]`UORK^1OY9>7/,>FS:/KNC:)#:ZKI<_'U()D+51N!8
M5^1PY#<B7$[%P3P:+%CF*E&-$,>O]`\P/_SE/H'FU-#NW\K6WY=WFB7&O@)]
M72^FU&*Y2$_%RJ8T)KQIAOTM4\4_Y1CDX3P\!%]+NT!_SD#Y5\[3:_\`E'^9
M_D;R_P#XQOORMUB[GU/R@DBQW%Y9:G`+69[4R%8S+$/B`9A7QQQD;@[-?;.#
M/QXL^&/&<<MX]2#MMTL/1ORS\X^>?.1\Q7OFO\NKS\O-*@O!'Y6M]4EA.HW-
MOQ'*2Y@MY)HXB&V`$C5&"40*HVYF@U.?.9G)C\.(/IOF1Y@77S?+GY]^2)]?
M_,37M9L/R2\]R^9X=*@M_*/YK>0]6M]/ENKCTF"QZCSNH&6.!^/$T:JUV[99
M"51JPZ+M72G+J)3&#(9`5&<)`6:_BW'+9];_`)5V7G73ORZ\G6/YBW\>J>=K
M;2K:/S%?1[\[@1@-R;]IAT9NYJ<JG5[/1=GQS1T\!F-SH7^._O9_V/R.1<Q\
MCV__`#D!Y9_+/R7Y+T%=%U'SGYD:RMC=>7](N=*M9X(;AY`LS-J]_I\3@%:,
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M%_T/M:I^:O\`-Y5_X&^Q]/FO^%_T/]DW3\U?YO*OW7V/I\U_PO\`H?[)U/S5
M_F\J_=?8^GS7_"_Z'^R=3\U?YO*OW7V/I\U_PO\`H?[)U/S5_F\J_=?8^GS7
M_"_Z'^R:I^:O\WE7_@;['T^:_P"%_P!#_9-T_-7^;RK]U]CZ?-?\+_H?[)JG
MYJ_S>5?^!OL?3YK_`(7_`$/]DW3\U?YO*OW7V/I\U_PO^A_LG4_-7^;RK]U]
MCZ?-?\+_`*'^R:I^:O\`-Y5_X&^Q]/FO^%_T/]DW3\U?YO*OW7V/I\U_PO\`
MH?[)JGYJ_P`WE7_@;['T^:_X7_0_V3=/S5_F\J_=?8^GS7_"_P"A_LG4_-3N
MWE4CN*7V/I\U_P`+_H?:_*O\U/\`G&Z_\E^<_*&I>?=7N[_RCH6K>:M6M=;7
MR<?/0O[[SC/831Z7%IHLM0:SM[']'D"X*QR(9!Z3BK8)&S;=I,)PX8P)LQ%/
MT'_(3R/K>B:E^8'GK6;>]T)//K:+;:7Y.NKAKF.PM=`L?T?'/$SLSCZX`)F$
MG[ROV_BKD7(?1^*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*O_];[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
,78J[%78J[%78J__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
